Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Journal of Medicinal Chemistry
|
February 17, 2012
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties
Simon Mathieu, Stefan N Gradl, Li Ren, et al.
Journal of Medicinal Chemistry
|
September 2, 2005
Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase
Kim F McClure, Yuriy A Abramov, Ellen R Laird, et al.
Cancer Discovery
|
June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Alexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 7, 2002
Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors
Michael A Letavic, Matt Z Axt, John T Barberia, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 23, 2005
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14
Julian A Blagg, Mark C Noe, Lilli A Wolf-Gouveia, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 1, 2006
Potent, selective pyrimidinetrione-based inhibitors of MMP-13
Lawrence A Reiter, Kevin D Freeman-Cook, Christopher S Jones, et al.
Journal of Medicinal Chemistry
|
January 25, 2007
Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity
Derin C D'Amico, Toshi Aya, Jason Human, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 16, 2007
Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13
Kevin D Freeman-Cook, Lawrence A Reiter, Mark C Noe, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 9, 2006
Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development
Kim F McClure, Michael A Letavic, Amit S Kalgutkar, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors
Steve Wenglowsky, Li Ren, Kateri A Ahrendt, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Journal of Medicinal Chemistry
|
February 17, 2012
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties
Simon Mathieu, Stefan N Gradl, Li Ren, et al.
Journal of Medicinal Chemistry
|
September 2, 2005
Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase
Kim F McClure, Yuriy A Abramov, Ellen R Laird, et al.
Cancer Discovery
|
June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Alexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 7, 2002
Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors
Michael A Letavic, Matt Z Axt, John T Barberia, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 23, 2005
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14
Julian A Blagg, Mark C Noe, Lilli A Wolf-Gouveia, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 1, 2006
Potent, selective pyrimidinetrione-based inhibitors of MMP-13
Lawrence A Reiter, Kevin D Freeman-Cook, Christopher S Jones, et al.
Journal of Medicinal Chemistry
|
January 25, 2007
Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity
Derin C D'Amico, Toshi Aya, Jason Human, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 16, 2007
Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13
Kevin D Freeman-Cook, Lawrence A Reiter, Mark C Noe, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 9, 2006
Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development
Kim F McClure, Michael A Letavic, Amit S Kalgutkar, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors
Steve Wenglowsky, Li Ren, Kateri A Ahrendt, et al.
Page
of 4